OncoCyte Corporation (OCX) Tops Q3 EPS by 32c

OncoCyte Corporation (NASDAQ: OCX) reported Q3 EPS of ($0.81), $0.32 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $430 thousand versus the consensus estimate of $437.5 thousand.

For earnings history and earnings-related data on OncoCyte Corporation (OCX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• DA Davidson Reiterates Buy Rating on Box, Inc. (BOX) on Secular Tailwinds for Demand
• Arena Group to rename as Paradium.AI, ticker changing to PAAI